FY2025 Earnings Estimate for OVID Issued By Lifesci Capital

Ovid Therapeutics (NASDAQ:OVID) – Research analysts at Lifesci Capital issued their FY2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a report issued on Monday, December 22nd. Lifesci Capital analyst F. Brisebois expects that the company will earn ($0.46) per share for the year. Lifesci Capital currently has a “Outperform” rating and a $4.00 target price on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.38) EPS.

Several other equities research analysts have also issued reports on OVID. Oppenheimer assumed coverage on shares of Ovid Therapeutics in a report on Thursday, October 9th. They issued an “outperform” rating and a $7.00 target price for the company. Leerink Partnrs raised shares of Ovid Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Wednesday, October 8th. Leerink Partners began coverage on shares of Ovid Therapeutics in a report on Monday, November 17th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, B. Riley reiterated a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $3.88.

Ovid Therapeutics Stock Down 1.4%

NASDAQ OVID opened at $1.79 on Wednesday. Ovid Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.01. The company has a quick ratio of 4.24, a current ratio of 4.24 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $127.11 million, a P/E ratio of -3.57 and a beta of 0.04. The stock’s 50-day moving average price is $1.51 and its 200-day moving average price is $1.09.

Ovid Therapeutics (NASDAQ:OVID) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%.

Hedge Funds Weigh In On Ovid Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its stake in Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after purchasing an additional 18,841 shares in the last quarter. Nuveen LLC purchased a new position in shares of Ovid Therapeutics during the first quarter valued at about $37,000. Affinity Asset Advisors LLC bought a new stake in shares of Ovid Therapeutics in the first quarter worth about $208,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Ovid Therapeutics by 15.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $359,000 after buying an additional 150,000 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Ovid Therapeutics by 12.8% in the first quarter. Acadian Asset Management LLC now owns 2,088,046 shares of the company’s stock worth $650,000 after buying an additional 237,445 shares in the last quarter. 72.24% of the stock is owned by hedge funds and other institutional investors.

Key Ovid Therapeutics News

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: Assenagon Asset Management disclosed a large third‑quarter purchase (an additional 488,956 shares, lifting its stake to 924,576 shares), signaling renewed institutional interest and potential support for the stock. Assenagon Asset Management S.A. Purchases 488,956 Shares of Ovid Therapeutics $OVID
• Positive Sentiment: LifeSci Capital initiated/expanded coverage with an Outperform/Buy stance and a $4.00 price target — this higher-profile coverage increases visibility and can attract new buyers into a small‑cap, low‑liquidity name. Ovid Therapeutics (NASDAQ:OVID) Research Coverage Started at Lifesci Capital
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on OVID, reinforcing positive analyst sentiment and providing additional dealer support for any momentum. Ovid Therapeutics’ (OVID) “Buy” Rating Reiterated at HC Wainwright
• Neutral Sentiment: Reported short‑interest data appears to be a reporting anomaly (entries show 0 shares and NaN change), so there is no clear short‑squeeze signal or meaningful short‑interest pressure at present.
• Negative Sentiment: Analyst models still expect ongoing quarterly losses (LifeSci estimates: FY2025 ≈ -$0.46, FY2026 ≈ -$0.38), underscoring that valuation depends on clinical progress or other corporate catalysts rather than near‑term profits. That persistent negative EPS profile limits how high the stock can rerate absent clinical or commercialization news. MarketBeat OVID profile (Lifescience estimates)

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.